Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Dianthus Therapeutics (DNTH) FCF Margin (2022 - 2025)

Dianthus Therapeutics has reported FCF Margin over the past 4 years, most recently at 7717.17% for Q3 2025.

  • Quarterly results put FCF Margin at 7717.17% for Q3 2025, down 673688.0% from a year ago — trailing twelve months through Sep 2025 was 3561.63% (down 239365.0% YoY), and the annual figure for FY2024 was 1255.57%, up 5267.0%.
  • FCF Margin for Q3 2025 was 7717.17% at Dianthus Therapeutics, up from 12403.11% in the prior quarter.
  • Over the last five years, FCF Margin for DNTH hit a ceiling of 313.26% in Q3 2022 and a floor of 12403.11% in Q2 2025.
  • Median FCF Margin over the past 4 years was 1713.16% (2024), compared with a mean of 2679.71%.
  • Biggest five-year swings in FCF Margin: surged 52404bps in 2024 and later crashed -1162238bps in 2025.
  • Dianthus Therapeutics' FCF Margin stood at 766.84% in 2022, then crashed by -239bps to 2596.06% in 2023, then rose by 20bps to 2072.02% in 2024, then plummeted by -272bps to 7717.17% in 2025.
  • The last three reported values for FCF Margin were 7717.17% (Q3 2025), 12403.11% (Q2 2025), and 2377.82% (Q1 2025) per Business Quant data.